Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study by Singh, Anurag K et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Radiation Oncology
Open Access Research
Simultaneous integrated boost of biopsy proven, MRI defined 
dominant intra-prostatic lesions to 95 Gray with IMRT: early results 
of a phase I NCI study
Anurag K Singh*1, Peter Guion2, Nancy Sears-Crouse2, Karen Ullman2, 
Sharon Smith2, Paul S Albert3, Gabor Fichtinger4, Peter L Choyke5, 
Sheng Xu6, Jochen Kruecker6, Bradford J Wood7, Axel Krieger8 and 
Holly Ning2
Address: 1Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, USA, 2Radiation Oncology Branch, National Cancer Institute, 
Bethesda, USA, 3Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA, 4School of 
Computing, Queens University, Kingston, Canada, 5Molecular imaging program, National Cancer Institute, National Institutes of Health, 
Bethesda, USA, 6Philips Research North America, Briarcliff Manor, USA, 7Diagnostic Radiology Dept., Clinical Center, National Institutes of 
Health, Bethesda, USA and 8Department of Mechanical Engineering, Johns Hopkins University, Baltimore USA
Email: Anurag K Singh* - singhanu@yahoo.com; Peter Guion - guionp@mail.nih.gov; Nancy Sears-Crouse - ncrouse@mail.nih.gov; 
Karen Ullman - karenullman@mail.nih.gov; Sharon Smith - smiths@mail.nih.gov; Paul S Albert - albertp@mail.nih.gov; 
Gabor Fichtinger - gabor@cs.queensu.ca; Peter L Choyke - pchoyke@mail.nih.gov; Sheng Xu - Sheng.Xu@philips.com; 
Jochen Kruecker - jochen.kruecker@philips.com; Bradford J Wood - bwood@mail.nih.gov; Axel Krieger - axel@jhu.edu; 
Holly Ning - hning@mail.nih.gov
* Corresponding author    
Abstract
Background:  To assess the feasibility and early toxicity of selective, IMRT-based dose escalation
(simultaneous integrated boost) to biopsy proven dominant intra-prostatic lesions visible on MRI.
Methods: Patients with localized prostate cancer and an abnormality within the prostate on endorectal
coil MRI were eligible. All patients underwent a MRI-guided transrectal biopsy at the location of the MRI
abnormality. Gold fiducial markers were also placed. Several days later patients underwent another MRI
scan for fusion with the treatment planning CT scan. This fused MRI scan was used to delineate the region
of the biopsy proven intra-prostatic lesion. A 3 mm expansion was performed on the intra-prostatic
lesions, defined as a separate volume within the prostate. The lesion + 3 mm and the remainder of the
prostate + 7 mm received 94.5/75.6 Gray (Gy) respectively in 42 fractions. Daily seed position was verified
to be within 3 mm.
Results: Three patients were treated. Follow-up was 18, 6, and 3 months respectively. Two patients had
a single intra-prostatic lesion. One patient had 2 intra-prostatic lesions. All four intra-prostatic lesions, with
margin, were successfully targeted and treated to 94.5 Gy. Two patients experienced acute RTOG grade
2 genitourinary (GU) toxicity. One had grade 1 gastrointestinal (GI) toxicity. All symptoms completely
resolved by 3 months. One patient had no acute toxicity.
Conclusion: These early results demonstrate the feasibility of using IMRT for simultaneous integrated
boost to biopsy proven dominant intra-prostatic lesions visible on MRI. The treatment was well tolerated.
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Background
There are over 200,000 new cases and nearly 30,000
deaths each year from prostate cancer [1]. Radiation ther-
apy (RT) is a mainstay of local therapy. It has been estab-
lished that biochemical disease free survival improves
with dose escalation to the prostate[2-5]. However, grow-
ing evidence indicates that normal tissue complications
also increase with increasing dose[4,6,7].
The dosimetric parameters which correlate with late toxic-
ity are being elucidated[2,7]. Advances in methods of pre-
cise radiation dose delivery, such as 3-dimensional
conformal radiation therapy and intensity modulated RT
(IMRT), may allow higher radiation doses to the prostate
while minimizing toxicity by limiting the amount of nor-
mal tissue irradiated[8]. However, normal tissues such as
the bladder and rectum abut the prostate. Therefore, dose
escalation to the entire prostate results in increased doses
to some portions normal tissue risking increased toxic-
ity[2,7,9].
In principle, selective dose escalation to a dominant intra-
prostatic lesion (simultaneous integrated boost) may
overcome this problem of increased complications with
increased dose. To date such selective dose escalation
strategies have focused on the use of brachyther-
apy[10,11]. Several publications have discussed the theo-
retical aspects of simultaneous integrated boost to one or
more lesions using external beam radiation therapy
alone[12-14]. None of these publications, however, have
reported on the results of implementing simultaneous
integrated boost in patients.
This trial was undertaken to assess the feasibility and tox-
icity of IMRT-based simultaneous integrated boost to
achieve selective intra-prostatic dose escalation to biopsy
proven dominant lesions visible on endorectal coil MRI.
In 42 fractions, the dominant lesion was treated to 94.5
Gy while the remainder of the prostate was treated to 75.6
Gy.
Methods
Eligibility and accrual
All patients underwent history and physical examination
as well as routine blood work including CBC, PSA, and
alkaline phosphatase. Imaging studies such as bone scan
were done as warranted. Eligible patients had: 1) biopsy
proven, localized adenocarcinoma of the prostate, 2) risk
of lymph node metastases less than 10% by Partin tables,
3) an MRI abnormality concordant with the location of at
least one sextant biopsy, and 4) were candidates for defin-
itive external beam radiotherapy. Prior to enrollment, all
patients provided written, informed consent in this IRB
approved protocol.
Study design
This is a phase I study to determine the maximum toler-
ated dose (MTD) with MRI-guided radiation dose escala-
tion to regions of biopsy proven cancer within the
prostate gland. There are 6 planned cohorts of 3 patients
each. The dose, to the biopsy proven region of cancer evi-
dent on MRI in this first cohort, was 94.5 Gy. The dose to
the region of cancer in the 6th and final cohort is planned
to be 152 Gy.
By design, if there are no acute dose limiting toxicities
(DLT) in 3 patients then patients will be accrued to the
next dose level. An acute DLT was defined as RTOG grade
3 or greater, acute GI or GU toxicity. If a DLT occurs in one
of three patients then an additional 3 patients will be
accrued to that dose level. If fewer than 2 of 6 patients
experience an acute DLT in the expanded cohort then
patients will be accrued to the next dose cohort. If 2 or
more of 6 patients experience a DLT then the MTD will be
exceeded and the prior, lower dose cohort will be consid-
ered the MTD.
Magnetic resonance imaging
Endorectal coil MRI was performed at 3 Tesla using a
Philips Achieva Scanner (Philips Medical Systems, Eind-
hoven NL.) The following pulse sequences were obtained:
T2 weighted fast spin echo, MR spectroscopy, dynamic
contrast enhanced MRI and delayed post contrast T1
weighted fast spin echo images. The scans were read by an
experienced radiologist and determined to be positive if
the T2 weighted scan was positive and one or both of the
other scans were also positive at the same location.
Biopsies and fiducial markers
All eligible patients underwent a subsequent MRI guided
biopsy procedure to document the presence of prostate
cancer at the location of the MRI abnormality. As previ-
ously described, biopsies were performed under direct
MRI guidance [15,16] or real time ultrasound/MRI
fusion[17,18]. All areas read as moderately or highly sus-
picious by the radiologist were biopsied. A total of 10
biopsies (half for pathology and half for our tissue bank)
were allowed. Additionally, gold fiducial markers were
also placed during this procedure. Generally, these mark-
ers were placed in the left middle, right middle, apex, and
base of the prostate.
Radiation therapy
Approximately one week later, with the seeds in place,
patients underwent another MRI scan which was fused
with the treatment planning CT scan. MR and CT fusion
was done using the Eclipse treatment planning software
and manually verified and optimized by checking the seed
position in both scans. This fused MRI scan was used to
delineate the region of the biopsy proven intra-prostaticRadiation Oncology 2007, 2:36 http://www.ro-journal.com/content/2/1/36
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lesion. A 3 mm expansion was performed on this intra-
prostatic lesion, defined as a separate volume within the
prostate. The lesion + 3 mm received 94.5 Gy in 2.25 Gy
daily fractions while the remainder of the prostate + 7 mm
received 75.6 Gy in 1.8 Gy daily fractions. If needed, the
seminal vesicles were allowed to be treated to 54 Gy.
No volume 4 mm beyond the lesion + 3 mm was allowed
to receive a dose beyond 75.6 Gy. Less than 25% of the
rectal volume was allowed to receive more than 70 Gy. No
more than 40% of the bladder was allowed to receive
more than 65 Gy. Maximum point dose to the rectum and
bladder was limited to 80.5 Gy. Attempts were made to
limit the prostatic urethra to 80 Gy. Though this did not
occur in the current cohort, if the urethral constraint was
not met, then specific authorization would be required by
the principal investigator to proceed with treatment.
Prior to each fraction, seed position was verified to be
within 3 mm of the planned position by electronic portal
imaging.
On treatment and follow-up evaluations
Patients were seen by a physician weekly while on treat-
ment. Upon completion of therapy, follow-up visits
occurred at 2, 4, and 8 weeks, 3 months, 6 months, then
every 6 months until 3 years. Formal toxicity measures
were obtained and recorded at baseline, at weeks 5 and 7
of therapy (when radiation therapy was nearly complete),
and at each follow-up visit. These toxicity measures
included Radiation Therapy Oncology Group (RTOG)
acute (within 120 days of completion of radiation) and
late toxicity grading and Expanded Prostate Cancer Index
Composite (EPIC) self-assessment questionnaires[19].
Statistical analysis
Summary statistics, such as sample proportions, listing of
values for each patient, and range of values were used to
describe the patient characteristics. Characteristics of radi-
ation dosimetry were described using maximum dose and
percent volume of structures receiving greater than thresh-
old dose.
Results
Three patients were treated. Follow-up was 18, 6, and 3
months respectively. The first and third patients had a sin-
gle, biopsy confirmed intra-prostatic lesion. The second
patient had 2 intra-prostatic lesions. All 4 intra-prostatic
lesions, with margin, were successfully targeted by MR
guided biopsy, (Figures 1a–1c.) These intra-prostate
lesions were targeted, biopsied, marked with a fiducial
marker, and treated to 94.5 Gy while the remainder of the
whole prostate was treated to a minimum of 75.6 Gy (Fig-
ure 2.) Maximum and minimum doses to critical struc-
tures are summarized in Table 1. Of the planning target
volumes, at least 97% of prostate and 90% lesion volumes
were covered by the prescription dose.
Two patients experienced acute RTOG grade 2 GU toxic-
ity. One had grade 1 GI toxicity. These symptoms com-
pletely resolved by 3 months. One patient had no acute
toxicity.
In patient 1, the single targeted biopsy was positive. In
patient 2, both highly suspicious lesions were positive
(Figure 2.) In patient 3, the highly suspicious lesion on
MR yielded no malignant tissue histologically (but did
demonstrate chronic inflammation) on 4 targeted biop-
sies while the moderately suspicious lesion on MR yielded
4 of 4 biopsies positive for Gleason score 6 prostate cancer
(Figure 3.)
Discussion
The early results of this trial demonstrate the feasibility of
using IMRT-based simultaneous integrated boost to selec-
tively increase dose to biopsy proven dominant intra-pro-
static lesions visible on MRI. The treatment was well
tolerated. All patients achieved resolution of treatment
related gastrointestinal and genitourinary symptoms on
the RTOG scale.
These findings are consistent with previous dosimetric
analyses which reported that, in theory, a external beam
radiation therapy based simultaneous integrated boost
dose to a MRI defined dominant intra-prostatic lesion(s)
should have acceptable toxicity[12-14].
Table 1: Doses to Critical Structures
Rectum Bladder Uretha
Patient Maximum Dose 
(Gy)
% Vol > 70 Gy Maximum Dose 
(Gy)
% Vol > 65 Gy 
(cubic centimeters 
(cc) > 65 Gy)
Maximum Dose 
(Gy)
1 80.4 7.34% 80.3 10.42% (20.13 cc) 78.4
2 78.1 9.4% 78.2 40% (18.4 cc) 78.5
3 79.9 6.18% 80.5 10.67% (21.56 cc) 79.2Radiation Oncology 2007, 2:36 http://www.ro-journal.com/content/2/1/36
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Pickett et al. showed that an early form of IMRT could be
1a: Dynamic Contrast Enhanced (DCE) MR image showing region of increased gadolinium uptake in the left peripheral zone Figure 1
1a: Dynamic Contrast Enhanced (DCE) MR image showing region of increased gadolinium uptake in the left peripheral zone. 
1b: MRI guided biopsy showing needle in the same region as in frame a. Pathology showed Gleason Score 7 disease. Immedi-
ately afterward, a fiducial marker was also placed in this location. 1c: Treatment planning image showing a fiducial marker in 
same region as figure a and b. The target was defined by fusing a treatment planning MRI (not shown and without an endorectal 
coil in place) with the treatment planning CT. The isodose lines are shown on the CT where the fiducial marker is best seen. 
The planning target volume of the intra-prostatic lesion is shown in fuschia. The 94.5 Gy isodose line is shown in green. The 
planning target volume of the prostate is shown in blue. The 75.6 Gy isodose line is shown in red.
Radiation dose plan showing anterior view on the left panel and lateral view on the right panel Figure 2
Radiation dose plan showing anterior view on the left panel and lateral view on the right panel. This 56 year old patient had 2 
areas on prostate MRI suspicious for cancer. MR guided biopsies of these suspicious areas were performed. Both suspicious 
areas were positive for Gleason Score 6 prostate cancer. The 94.5 Gy dose clouds of the simultaneous integrated boost are 
seen in the left and right mid gland as yellow rings around the contoured MR abnormalities of biopsy proven cancer. The 75.6 
Gy dose cloud covering the remainder of the prostate is represented by red rings. The rectum (green) and bladder (light 
brown) are also shown.Radiation Oncology 2007, 2:36 http://www.ro-journal.com/content/2/1/36
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used to deliver 90 Gy to a single MRI-defined intra-pros-
tatic lesion while treating the rest of the prostate to 70 Gy
in 1.8 Gy daily fractions. In fact, this plan with simultane-
ous integrated boost to the dominant intra-prostatic
lesion actually produced a slightly lower rectal dose than
a standard three dimensional conformal radiation plan
giving only 70 Gy to the prostate[13]. Recently, van Lin et
al. performed a similar analysis on 5 patient data sets
comparing IMRT plans which gave 78 Gy to the prostate
with IMRT plans giving 70 Gy to the whole prostate while
giving a 90 Gy simultaneous integrated boost to a single
MR-defined dominant intra-prostatic lesion in each
patient. Echoing Pickett et al., the authors found that rec-
tal doses, and therefore presumably complications, would
have been lower in the group receiving simultaneous inte-
grated boost[12].
In the current study, 2 patients had a single intra-prostatic
lesion. One patient had 2 MRI defined, biopsy proven
intra-prostatic lesions. The successful treatment of this
patient demonstrates the practical ability to safely deliver
simultaneous integrated boosts to 2 intraprostatic lesions
without significant toxicity. The theoretical feasibility of
this approach was reported by Xia et al. who ran multiple
IMRT plans on a single selected case with 2 intraprostatic
lesions. The authors concluded that it was technically fea-
sible to concurrently treat multiple selected high-risk
regions within the prostate to 90 Gy and the remaining
prostate to 75.6 Gy. Doses to the rectum and the bladder
suggested that Grade 2 complications should occur in sig-
nificantly less than 10%[14].
Consistent with these theoretical findings, all 3 patients in
the current study achieved resolution of acute treatment
related gastrointestinal and genitourinary symptoms as
described by the RTOG scale. No late toxicities have been
observed. In fact, in follow up, one patient has shown
marked improvement from baseline, pre-treatment symp-
toms of urinary frequency.
Certainly, these early results are encouraging. However, 2
substantial hurdles remain prior to wide implementation
of this approach. First, it remains unclear how well MR
scans differentiate regions of prostate cancer from regions
of prostate inflammation. Anastasiadis et al., in a series of
prostate biopsies performed under direct MR guidance,
noted that prostatitis and prostate cancer have a quite sim-
ilar appearance on MR[20].
Our data concur with this finding[21]. Figure 3 illustrates
that MR spectroscopy and DCE imaging are often unable
to discriminate cancer from inflammation of the prostate.
Therefore, intra-prostatic lesions as defined by MR should
not be targeted for simultaneous integrated boost in the
absence of biopsy proven cancer in that region. Second,
the long term effects of this treatment strategy, though
assumed to be minimal, have yet to be established.
Simultaneous integrated prostate boost with IMRT there-
fore remains experimental and should only be performed
on IRB approved, prospective trials with appropriate
informed consent and planned long term follow-up.
Conclusion
These early results demonstrate the feasibility, with excel-
lent early toxicity, of using IMRT for simultaneous inte-
grated boost to biopsy proven prostate cancer visible on
MRI. Long term follow up with larger numbers of patients
are needed prior to wide implementation of this tech-
nique. Simultaneous integrated IMRT boost to intra-pros-
tatic lesions should only be undertaken on institutional
review board approved trials with image guided biopsy
evidence of disease in that location.
False positive endorectal coil MRI lesion with contralateral  malignant lesion Figure 3
False positive endorectal coil MRI lesion with contralateral 
malignant lesion. 3a: Color chart obtained from the MR 
Spectroscopy showing an elevated ratio of choline to citrate 
(depicted in red) in the right mid gland of the prostate. 3b: 
Area of the right mid gland (shown as a square in both a and 
b) on the T2 weighted MRI of the prostate where a high 
choline to citrate ratio was observed, indicating a highly sus-
picious for prostate cancer region of low signal intensity. 3c: 
Overlay of the T2 MRI and the color map of the MR Spec-
troscopy. 3d: T2 MRI of the prostate. To avoid any suspicion 
of sampling error, 8 biopsies were performed on the left and 
right mid glands. All 4 biopsies from the left mid (read as 
moderately suspicious for prostate cancer) were positive for 
Gleason Score 6 disease. All 4 biopsies from the right mid 
gland (read as highly suspicious for prostate cancer) demon-
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